ArticleBMC cancer2025
Synthetic lethality of EZH2 and DNMT Inhibition suppresses neuroblastoma proliferation via MYCN destabilization.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Epigenetic Regulation of Trk Receptors and Neurotrophic Signalling in Neuroblastoma: Mechanisms, Plasticity, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundEnhancer of Zeste Homolog 2 (EZH2) is highly expressed in various cancers and is thought to contribute to cancer malignancy through the methylation of lysine 27 on histone H3 (H3K27). Therefore, EZH2 is an H3K27 methylase and a target of cancer epigenetic treatments. Here, we investigated the effects and functions of a small-molecule EZH2 inhibitor (EZH2i) in aggressive neuroblastoma (NB).
methodsTo identify genes associated with the sensitivity to EZH2i, we classified NB cell lines into sensitive and resistant groups. EZH2i suppressed proliferation and induced cell cycle arrest in EZH2-sensitive NB cells. Transcriptome analysis revealed the de-repression of gene sets related to differentiation and cell cycle arrest. To investigate whether the gene repression in resistant cells is mediated by mechanisms other than H3K27 methylation, methylome analysis was conducted to evaluate the significance of DNA methylation. The effect of combined treatment with an EZH2 inhibitor and a DNA methylation inhibitor (DNMTi) on the growth of resistant NB cells was subsequently assessed both in vitro and in vivo, even in cells resistant to EZH2 inhibition.
resultsGenes such as TRIM63, VSTM2L, GPNMB, and TIMP3, which are de-repressed by EZH2is in sensitive cells. Furthermore, the promoters of some of these genes are hypermethylated in EZH2i-resistant cells and NB tissues. Additionally, the combined treatment with EZH2i and 5-aza-dC significantly inhibited cell proliferation with MYCN destabilization at protein level, c-MYC suppression at RNA and protein level and induced a robust differentiation phenotype.
conclusionsOur study identified gene expression profiles that can distinguish the responsiveness to EZH2i in neuroblastoma, and demonstrated that DNMTi not only de-repression in gene expression but also suppress neuroblastoma growth through inhibition of MYC. These results confirm the importance of epigenetic regulation in NB biology and provide information for developing epigenetic therapies for patients with advanced NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.